Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financia... (as a service for its research customers....)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results

Date:8/7/2008

as a service for its research customers. Inovio will receive a royalty on such services.

Subsequent to the quarter, we announced the signing of a definitive merger agreement with VGX Pharmaceuticals, Inc., a privately-held DNA vaccine developer, which provides for the issuance of Inovio Biomedical securities in exchange for all of the outstanding securities of VGX Pharmaceuticals, subject to completion of the registration of the Inovio Biomedical securities to be issued with the U.S. Securities and Exchange Commission (SEC), receipt of approval from both companies' stockholders of the transaction, listing approval from the American Stock Exchange and other customary closing conditions. The parties expect to complete the merger in the fourth quarter of 2008, however, the actual timing of the transaction will depend on a number of factors, some of which are beyond either company's control.

About Inovio Biomedical Corporation

Inovio Biomedical (AMEX: INO) is focused on developing multiple DNA-based immunotherapies and DNA vaccines. Inovio is a leader in developing human applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Human data has shown that Inovio's electroporation-based DNA delivery technology can significantly increase gene expression and immune responses from DNA vaccines. Immunotherapy partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the U.S. Army, National Cancer Institute, and International Aids Vaccine Initiative. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology, our operatio
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine news :

1. Stiefel Laboratories Completes Acquisition of Barrier Therapeutics
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. InteKrin Therapeutics Announces $20 Million Series C Financing
5. Transition Therapeutics Announces No Material Change
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8
7. DIA/AAPS Co-Sponsored Conference to Examine the Immunogenicity of Therapeutic Proteins
8. Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit
9. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
10. Neurotherapeutics presents special issue on new treatments for Alzheimers disease
11. Horizon Therapeutics Names Timothy P. Walbert as President and CEO

Post Your Comments:

Related Image:

Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results

(Date:12/14/2009)... Dec. 14 Tough Enough To Wear Pink(TM) ... cancer, celebrated its fifth anniversary at the signature ... Wrangler National Finals Rodeo (Wrangler NFR) in Las ... rough-and-tumble rodeo cowboys, the support of the western ... sold-out crowd sported pink shirts, hats, bracelets and ...

(Date:12/14/2009)... higher than generally thought, raising concerns about increased risk for cancer, ... San Francisco (UCSF) imaging specialists. , ... San ... CT procedures vary widely and are higher than generally thought, raising ... led by University of California, San Francisco (UCSF) imaging ...

(Date:12/14/2009)... Federation of America (HFA) expresses its concern regarding ... 929 and the American Red Cross of Pennsylvania ... skilled workers to provide clean, safe blood to ... as clotting factor for use in treating hemophilia ... of Blood Services at the American Red Cross ...

(Date:12/14/2009)... the bump in odds is small and shouldn,t worry ... News) -- Older women who take antidepressants may have ... and death compared to women not on the medications, ... be different from clinical significance," stressed Dr. Jordan W. ... School, and lead author of a report in the ...

(Date:12/14/2009)... might lead to better treatments for asthma, COPD, researchers ... have identified five genetic variants that influence lung function, ... for lung diseases. , The international team of researchers ... the 2.5 million sites across the human genome in ... the team to the five common genetic variants associated ...

Breaking Medicine News(10 mins):Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5 Health News:HFA Voices Blood Safety Concerns 2 Health News:Antidepressants May Raise Women's Stroke Risk 2 Health News:Antidepressants May Raise Women's Stroke Risk 3

[0] Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary [0] Variable Doses of Radiation Raise Safety Concerns for CT Procedures [0] HFA Voices Blood Safety Concerns [0] Antidepressants May Raise Women's Stroke Risk [0] Five Gene Variants May Be Linked to Lung Disease

... DRAXIS Health Inc, (TSX:,DAX) (NASDAQ: DRAX ) has applied ... Issuer Bid (NCIB), subject to TSX approval, to buy back ... maximum number of common shares which may be purchased for,cancellation ... which,represents 10% of the common shares in the public float ...

... G. Komen for the Cure, Participates in Nationwide Campaign Challenging U.S. to ... ... Jan. 11, elected officials,will join advocates from the San Francisco Bay Area ... pink, highlighting the urgent need,to address disparities in breast cancer early detection ...

... Alarming New HIV Rates; Governor Should Cut,Bureaucracy, Corporate ... Healthcare,Foundation (AHF) today urged California Governor Arnold Schwarzenegger ... cuts in AIDS services,that will reduce and threaten ... HIV/AIDS as he seeks to close a $14 ...

... 10 The U.K. is currently dealing,with an outbreak ... infect,hundreds of thousands of people in the coming weeks. ... the U.K.,s Health Protection Agency,(HPA), says doctors and hospitals ... People suffering from the virus are being asked to ...

... blood cell numbers , A common treatment ... (rbcs) caused by their insufficient production, excessive destruction, or ... a hormone that stimulates the production of rbc precursors ... do not respond to treatment with Epo. However, a ...

... study shows preconditioning cardiac cells helps organ better tolerate loss ... Just as daily runs can prepare you to survive a ... could condition cardiac cells to better withstand the damage of ... of Cincinnati suggests. , Ultimately, if validated in humans, these ...

DRAXIS Announces Application for Normal Course Issuer Bid San Francisco City Hall Turns Pink, Draws Attention to Disparities in Breast Cancer Screening, Treatment AHF to Schwarzenegger: 'AIDS Cuts Are Deadly'CeraLyte ORS to Prevent Dehydration from Norovirus Outbreak JCI online early table of contents: Jan. 10 2008 Priming Heart Before an Attack Could Limit Damage

(Date:12/14/2009)... we have been tracking Tianyin Pharmaceuticals (NYSE Amex: ... up had been with the potential dilution from "in-the-money" ... guidance of $11.3 million represents a 43.0% increase from ... the increase in shares poses some uncertainty regarding the ... share price and the Treasury method of accounting for ...

(Date:12/14/2009)... -- According to Millennium Research Group (MRG), the ... use of safety devices for small-bore connectors for ... driver of the enteral feeding device markets in ... US and European Markets for Enteral Feeding Devices ... segment will experience the greatest impact from facilities ...

(Date:12/14/2009)... Manchester Pharmaceuticals, Inc.(TM) announced today the ... On October 22, 2009, the US Food and ... for patients suffering from gallstones in whom surgery ... or advanced age. ,, Chenodal prescriptions have started ... Health Resources ("Centric"), a specialty pharmacy company. ...

Breaking Medicine Technology:GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms 2 Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2 Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3 Manchester Announces Availability of Chenodal(TM) 2 GenVaults GenSolve 28TM 29 Reagents Enable State of the Art Genomic Analysis of Dried Blood Spots 53720 1 GenVaults GenSolve 28TM 29 Reagents Enable State of the Art Genomic Analysis of Dried Blood Spots 53720 2 GenVaults GenSolve 28TM 29 Reagents Enable State of the Art Genomic Analysis of Dried Blood Spots 53720 3 Effient 28TM 29 is Now Available in Pharmacies 53716 1 Effient 28TM 29 is Now Available in Pharmacies 53716 2 Effient 28TM 29 is Now Available in Pharmacies 53716 3 Effient 28TM 29 is Now Available in Pharmacies 53716 4 BioNeutrals Ygiene 28TM 29 Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing 13384 1 BioNeutrals Ygiene 28TM 29 Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing 13384 2 BioNeutrals Ygiene 28TM 29 Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing 13384 3

[0] GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms [0] Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 [0] Manchester Announces Availability of Chenodal(TM)

... the majority of acute lymphoblastic leukemia relapse cases arise from ... , MEMPHIS, Tenn., Nov. 27 ... distinctive genetic changes in the cancer cells of children with ... a pathway to designing treatments for ALL relapse in children ...

... and University of Louisville hand surgeons performed ... resident, Jan "Erik" Hondusky, at Louisville,s Jewish Hospital Hand ... procedure began around noon and was completed shortly after ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20081125/DC48555-a ...

Other Medicine Technology:St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2 St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3 Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2 Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3

St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center

Alexander periosteal elevators....

Lambotte periosteal elevators....

Cottle periosteal & skin elevator, 7 1/2", slightly curved blade, 9 mm wide....

Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....

Medicine Products:

Alexander Periosteal Elevators Lambotte Periosteal Elevators Cottle Periosteal & Skin Elevator Dolwick-Reich Condyle Periosteal Elevator

Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financia...(as a service for its research customers....),Health